To identify and evaluate available data on pediatric echinocandin use.
DATA SOURCES
A PubMed search, limited to English-language articles, was conducted (1990-August 2009) using the search terms echinocandin, pediatric, child, pharmacokinetics, caspofungin, micafungin, and anidulafungin. Additional articles were retrieved from citations of selected references.
STUDY SELECTION AND DATA EXTRACTION
Relevant information on the pharmacology, pharmacokinetics, efficacy, and safety of echinocandins in children was selected. Clinical trials, retrospective reviews, and case series were identified and evaluated. Data from these sources were included in this review.
DATA SYNTHESIS
Caspofungin is the only echinocandin approved by the Food and Drug Administration for use in children. Pediatric pharmacokinetics has been evaluated with all 3 echinocandins but is limited with anidulafungin. Micafungin is the most well-studied agent in prospective clinical trials for antifungal prophylaxis in stem cell transplantation and treatment of invasive fungal infections. Caspofungin has been studied prospectively for febrile neutropenia and treatment of invasive fungal infections, but most published data are from retrospective reviews or case reports. One case report of anidulafungin for neonatal candidiasis has been published. The role of echinocandins in the management of invasive pediatric fungal infections has expanded. Micafungin and caspofungin are recommended as primary or alternative treatment of candidemia and esophageal or invasive candidiasis, and as salvage therapy for invasive aspergillosis. Micafungin is recommended for neutropenic prophylaxis in stem cell transplantation, while caspofungin may be used in febrile neutropenia as an alternative to azoles. Dosing has been well established for caspofungin only in children 3 months of age and above. Anidulafungin should be avoided in children until more pharmacokinetic and clinical data become available.
CONCLUSIONS
Further comparative trials are needed to more clearly define the role of echinocandins, either as monotherapy or in combination for difficult-to-treat infections, in the pediatric population.
. SobelJDRevankarSG.Echinocandins—first-choice or first-line therapy for invasive candidiasis?N Engl J Med2007;356:2525–6.
5.
. GeorgopapadakouNH.Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors. Expert Opin Investig Drugs2001;10:269–80. DOI 10.1517/13543784.10.2.269.
6.
. MazurPMorinNBaginskyWDifferential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase. Mol Cell Biol1995;15:5671–81.
7.
. DouglasCMD'IppolitoJASheiGJIdentification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother1997;41:2471–9.
8.
. DenningDW.Echinocandins and pneumocandins—a new antifungal class with a novel mode of action. J Antimicrob Chemother1997;40:611–4.
9.
. PfallerMABoykenLHollisRJIn vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol2008;46:150–6. Epub 23 Nov 2007. DOI 10.1128/JCM.01901-07.
10.
. AntachopoulosCMeletiadisJSeinTRoilidesEWalshTJ.Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob Agents Chemother2008;52:321–8. Epub 17 Oct 2007. DOI 10.1128/AAC.00699-07.
11.
. WiederholdNPNajvarLKBocanegraRMolinaDOlivoMGraybillJR.In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob Agents Chemother2007;51:1616–20. Epub 20 Feb 2007. DOI 10.1128/AAC.00105-07.
12.
. PaderuPGarcia-EffronGBalashovSDelmasGParkSPerlinDS.Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother2007;51:2253–6. Epub 9 Apr 2007. DOI 10.1128/AAC.01536-06.
13.
. PfallerMABoykenLHollisRJMesserSATendolkarSDiekemaDJ.Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J Clin Microbiol2006;44:3533–8. DOI 10.1128/JCM.00872-06.
14.
. IkedaFSaikaTSatoYAntifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan. Med Mycol2009;47:145–8. Epub 1 Aug 2008. DOI 10.1080/13693780802262123.
15.
. FeldmesserMKressYMednickACasadevallA.The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J Infect Dis2000;182:1791–5. DOI 10.1086/317614.
16.
. AlmyroudisNGSuttonDAFothergillAWRinaldiMGKusneS.In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother2007; 51:2587–90. Epub 25 Apr 2007. DOI 10.1128/AAC.00452-07.
17.
. ZengJKameiKZhengYNishimuraK.Susceptibility of Pseudallescheria boydii and Scedosporium apiospermum to new antifungal agents. Nippon Ishinkin Gakkai Zasshi2004;45:101–4.
18.
. Espinel-IngroffA.Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol1998;36:2950–6.
19.
. ItoMNozuRKuramocTProphylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice. Antimicrob Agents Chemother2000;44:2259–62.
20.
. CaoCLiuWLiRWanZQiaoJ.In vitro interactions of micafungin with amphotericin B, itraconazole or fluconazole against the pathogenic phase of Penicillium marneffei. J Antimicrob Chemother2009;63:340–2. Epub 5 Dec 2008. DOI 10.1093/jac/dkn494.
21.
. Ruiz-CendoyaMRodriguezMMMarineMPastorFJGuarroJ.In vitro interactions of itraconazole and micafungin against clinically important filamentous fungi. Int J Antimicrob Agents2008;32:418–20. DOI 10.1016/j.ijantimicag.2008.05.015.
22.
. ShalitIShadkchanYMircusGOsherovN.In vitro synergy of caspofungin with licensed and novel antifungal drugs against clinical isolates of Fusarium spp. Med Mycol2009;47:457–62.
23.
. MarineMSerenaCPastorJQuindosGCarrilloAJGuarroJ.In vitro activity of micafungin combined with itraconazole against Candida spp. Int J Antimicrob Agents2007;30:463–5. Epub 19 Aug 2007. DOI 10.1016/j.ijantimicag.2007.06.022.
24.
. AndesDMarchilloKLowtherJBryskierAStamstadTConklinR.In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother2003;47:1187–92.
25.
. AndesDDiekemaDJPfallerMAIn vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother2008;52:539–50. Epub 12 Dec 2007. DOI 10.1128/AAC.01061-07.
26.
. AndesDRDiekemaDJPfallerMAMarchilloKBohrmuellerJ.In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob Agents Chemother2008;52:3497–503. Epub 16 July 2008. DOI 10.1128/AAC.00478-08.
27.
. LouieADezielMLiuWDrusanoMFGumboTDrusanoGL.Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother2005;49:5058–68. DOI 10.1128/AAC.49.12.5058-5068.2005.
28.
. VenisseNGregoireNMarliatMCouetW.Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans. Antimicrob Agents Chemother2008;52:937–43. Epub 9 Jan 2008. DOI 10.1128/AAC.01030-07.
29.
. AntachopoulosCMeletiadisJSeinTRoilidesEWalshTJ.Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species. Antimicrob Agents Chemother2007;51:881–7. Epub 6 Dec 2006. DOI 10.1128/AAC.01160-06.
30.
. WiederholdNPKontoyiannisDPChiJPharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis2004;190:1464–71. Epub 10 Sep 2004. DOI 10.1086/424465.
31.
. CotaJMGrabinskiJLTalbertRLIncreases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofungin. Antimicrob Agents Chemother2008;52:1144–6. Epub 19 Dec 2007. DOI 10.1128/AAC.01542-07.
. RamageGVandeWalleKBachmannSPWickesBLLopez-RibotJL.In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother2002;46:3634–6.
34.
. HajduRThompsonRSundelofJGPreliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother1997;41:2339–44.
35.
. WalshTJAdamsonPCSeibelNLPharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother2005;49:4536–45. DOI 10.1128/AAC.49.11.4536-4545.2005.
36.
. NeelyMJafriHSSeibelNThe pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother2009;53:1450–6.
37.
. Saez-LlorensXMaciasMMaiyaPPharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother2009;53:869–75. Epub 17 Dec 2008. DOI 10.1128/AAC.00868-08.
38.
. SeibelNLSchwartzCArrietaASafety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother2005;49:3317–24. DOI 10.1128/AAC.49.8.3317-3324.2005.
39.
. TabataKKatashimaMKawamuraATanigawaraYSunagawaK.Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections. Biol Pharm Bull2006;29:1706–11.
40.
. HeresiGPGerstmannDRReedMDThe pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J2006;25:1110–5. DOI 10.1097/01.inf.0000245103.07614.e1.
41.
. HopeWWMickieneDPetraitisVThe pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis2008;197:163–71. DOI 10.1086/524063.
42.
. HopeWWSeibelNLSchwartzCLPopulation pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother2007;51:3714–9. Epub 20 Jul 2007. DOI 10.1128/AAC.00398-07.
43.
. DamleBStogniewMDowellJ.Pharmacokinetics and tissue distribution of anidulafungin in rats. Antimicrob Agents Chemother2008; 52:2673–6. Epub 30 Apr 2008. DOI 10.1128/AAC.01596-07.
44.
. BenjaminDKJrDriscollTSeibelNLSafety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother2006;50:632–8. DOI 10.1128/AAC.50.2.632-638.2006.
45.
. van BurikJARatanatharathornVStepanDEMicafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis2004;39:1407–16. DOI 10.1086/422312.
46.
. KooASungLAllenUEfficacy and safety of caspofungin for the empiric management of fever in neutropenic children. Pediatr Infect Dis J2007;26:854–6. DOI 10.1097/INF.0b013e318067b4d1.
47.
. OdioCMArayaRPintoLECaspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J2004;23:1093–7.
48.
. NatarajanGLulic-BoticaMRongkavilitCPappasABedardM.Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol2005;25:770–7. Epub 14 Oct 2005. DOI 10.1038/sj.jp.7211380.
49.
. MerlinEGalambrunCRibaudPEfficacy and safety of caspofungin therapy in children with invasive fungal infections. Pediatr Infect Dis J2006;25:1186–8. DOI 10.1097/01.inf.0000246844.42159.a0.
50.
. GrollAHAttarbascASchusterFRTreatment with caspofungin in immunocompromised paediatric patients: a multicentre survey. J Antimicrob Chemother2006;57:527–35. Epub 25 Jan 2006. DOI 10.1093/jac/dkl009.
51.
. FranklinJAMcCormickJFlynnPM.Retrospective study of the safety of caspofungin in immunocompromised pediatric patients. Pediatr Infect Dis J2003;22:747–9.
52.
. Queiroz-TellesFBerezinELevergerGMicafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J2008;27:820–6. DOI 10.1097/INF.0b013e31817275e6.
53.
. Ostrosky-ZeichnerLKontoyiannisDRaffalliJInternational, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis2005;24:654–61. DOI 10.1007/s10096-005-0024-8.
54.
. DenningDWMarrKALauWMMicafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect2006;53:337–49. DOI 10.1016/j.jinf.2006.03.003.
55.
. CesaroSGiacchinoMLocatelliFSafety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. BMC Infect Dis2007;7:28. Epub 20 Apr 2007. DOI 10.1186/1471-2334-7-28.
56.
. CesaroSToffoluttiTMessinaCSafety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. Eur J Haematol2004; 73:50–5. DOI 10.1111/j.1600-0609.2004.00254.x.
57.
. YalazMAkisuMHilmiogluSCalkavurSCakmakBKultursayN.Successful caspofungin treatment of multidrug resistant Candida parapsilosis septicaemia in an extremely low birth weight neonate. Mycoses2006;49:242–5. DOI 10.1111/j.1439-0507.2006.01220.x.
58.
. MrowczynskiWWojtalikM.Caspofungin for Candida endocarditis. Pediatr Infect Dis J2004;23:376.
59.
. WertzKKPretzlaffRK.Caspofungin in a pediatric patient with persistent candidemia. Pediatr Crit Care Med2004;5:181–3.
60.
. CastagnolaEMachettiMCappelliBCaspofungin associated with liposomal amphotericin B or voriconazole for treatment of refractory fungal pneumonia in children with acute leukaemia or undergoing allogeneic bone marrow transplant. Clin Microbiol Infect2004;10:255–7.
61.
. ZaoutisTEJafriHSHuangLMA prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics2009;123:877–84. DOI 10.1542/peds.2008-1158.
62.
. PappasPGKauffmanCAAndesDClinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis2009;48:503–35. Epub 5 Feb 2009. DOI 10.1086/596757.
63.
. SegalBHFreifeldAGBadenLRPrevention and treatment of cancer-related infections. J Natl Compr Canc Netw2008;6:122–74.
64.
. WalshTJAnaissieEJDenningDWTreatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis2008;46:327–60. Epub 8 Jan 2008. DOI 10.1086/525258.
65.
. VariscoBMBennerKWPrabhakaranP.Neonatal peritoneal candidiasis successfully treated with anidulafungin add-onn therapy. Ann Pharmacother2009;43:1907–10. Epub 13 DOI 10.1345/aph.1M350.
